GTC Biotherapeutics and LFB Biotechnologies Enter Strategic Collaboration
Complete the form below to unlock access to ALL audio articles.
GTC Biotherapeutics, Inc. and LFB- Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire francais du Fractionnement et des Biotechnologies S.A.) have announced that they have entered into a strategic collaboration to develop selected recombinant plasma proteins and monoclonal antibodies using GTC’s transgenic production platform.
A Joint Steering Committee will agree on product development as well as commercialization plans.
GTC will be responsible for development of the production system for the products and will retain exclusive commercial rights to the products in North America.
LFB Biotechnologies will be responsible for clinical development and regulatory review of the first program of this collaboration, and will have exclusive commercial rights in Europe.
GTC and LFB Biotechnologies will hold co-exclusive rights in the rest of the world to the products developed through their collaboration.
The first program in this collaboration is for development of a transgenically produced recombinant form of human factor VIIa (rhFVIIa).
"This collaboration with LFB Biotechnologies is a significant step in the execution of our strategic plan to develop a robust pipeline of recombinant plasma proteins and monoclonal antibodies," stated Geoffrey F. Cox, Ph.D., GTC’s Chairman and Chief Executive Officer.
"LFB is a significant European company with broad experience in the development and marketing of plasma proteins as treatments for a wide range of medical conditions."
"We are very pleased to share our respective strengths to develop an abundant source of rhFVIIa and potentially recombinant forms of other plasma proteins and monoclonal antibodies."
"Thanks to this strategic alliance with GTC, we have assembled all the assets and skills of a worldwide success for our rhFVIIa," stated Christian Béchon, LFB’s Chairman and Chief Executive Officer.
"Our collaboration offers a unique opportunity to meet worldwide expanding patient needs with a technological breakthrough."
"With this agreement, LFB has access to the expertise and intellectual property of the world leader in animal transgenic technology."
